NCT05604287 is a Phase 1 clinical trial of ID119031166M in Healthy Participants, sponsored by IlDong Pharmaceutical Co Ltd.

Who is sponsoring NCT05604287?

NCT05604287 is sponsored by IlDong Pharmaceutical Co Ltd.

What drugs are being tested in NCT05604287?

Interventions in NCT05604287: ID119031166M, Placebo.

What condition does NCT05604287 study?

NCT05604287 studies Healthy Participants.

Is NCT05604287 still recruiting?

NCT05604287 is currently terminated. Last updated 11 July 2024.

Last reviewed 2024-07-11 · How we verify

NCT05604287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Terminated Phase 1 Last updated 11 July 2024

What this trial tests

Phase 1 trial testing ID119031166M in Healthy Participants in 67 participants. Terminated before completion.

Timeline

10 October 2022

Primary endpoint
12 April 2024

12 April 2024

Quick facts

Lead sponsor	IlDong Pharmaceutical Co Ltd
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	67
Start date	10 October 2022
Primary completion	12 April 2024
Estimated completion	12 April 2024
Sites	1 location across United States

Drugs / interventions tested

ID119031166M — full drug profile →
Placebo

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

IlDong Pharmaceutical Co Ltd — full company profile →

Who can join

Adults 18 to 70, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.
Jin P, Duan X, Huang Z, Dong Y, et al · · 2025 · cited 21× · PMID 40717128 · DOI 10.1038/s41392-025-02270-3

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other IlDong Pharmaceutical Co Ltd trials

Trials by the same sponsor.

NCT06635226 — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects · Phase 1 · recruiting
NCT06063291 — Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects · Phase 1 · completed
NCT05663879 — Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers · Phase 1 · unknown
NCT05259020 — To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy · Phase 1 · unknown
NCT04982705 — IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05604287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IlDong Pharmaceutical Co Ltd
Last refreshed: 11 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05604287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing